solute carrier family 37 member 2Genealiases: SPX2 · pp11662
Q-omics provides the consensus-scored SLC37A2 profile across patient tissues and cancer cell-line models. SLC37A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC37A2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLC37A2 RNA expression shows 14,935 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SLC37A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC37A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC37A2 survival associations across molecular data types. SLC37A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC37A2 RNA expression–survival associations across cancer types. High SLC37A2 expression shows unfavorable associations in LGG and STAD, but favorable associations in KIRC, ESCA, DLBC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC37A2 RNA expression.
This table summarizes SLC37A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC37A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC37A2 shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP, HNSC, BRCA and THCA. The KIRC box plot shows higher SLC37A2 RNA expression in tumor versus normal tissue (log2 FC = +2.270, t-test p < 0.001).
This table shows molecular features associated with SLC37A2 in patient tissues and cancer cell lines. In patient samples, SLC37A2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC37A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
